ElrySign
Nagpur, India· Est.
Saliva‑based AI diagnostic kit enabling 15‑minute early oral cancer detection.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $1.8M
AI Company Overview
Saliva‑based AI diagnostic kit enabling 15‑minute early oral cancer detection.
Oncology
Technology Platform
Saliva‑based biomarker assay combined with CRISPR‑Cas13a sensing and AI‑driven data analysis for rapid oral cancer detection.
Opportunities
Scaling the saliva‑based platform to other head‑and‑neck cancers and leveraging AI for broader biomarker panels could unlock multi‑disease screening markets.
Risk Factors
Regulatory clearance delays, reimbursement uncertainty, and competition from established oral cancer screening tools may hinder market adoption.
Competitive Landscape
Competitors include VELscope, brush cytology, and other saliva‑based tests; ErlySign differentiates with rapid 15‑minute results, AI analytics, and lower cost.